magnetic resonance imaging and photothermic therapy, 4, 5 clinical immunoassay, 6 pathogen detection, 7 and catalyzing reactions. 8 Jinwoo Cheon et al. have synthesized biocompatible heterostructured FePt-Au nanoparticles for multimodal biological detection. 9 Besides the magnetic-optical bifunctional nanoparticles mentioned above, the fabrication of fluorescent-magnetic bifunctional nanoparticles composed of quantum dots and magnetic nanoparticles has also attracted extensive attention. By means of encapsulation, direct reaction, and inorganic synthesis, fluorescent-magnetic bifunctional nanoparticles with different structures have been prepared successfully, and most of them have also been successfully applied in the fields of multimodal imaging, cell labeling and separation, intracellular spatial control, drug delivery, and so on. Of interest is that Wilson et al.
conducted a multiplexed protein detection based on fluorescent-magnetic nanoparticles, 24 the first multiplex assay with fluorescent-magnetic nanoparticles.
In the last few decades, cancers have become one of the major human diseases that ultimately result in death. Accurate, sensitive, and rapid diagnosis techniques for cancers and facile collection/isolation techniques for cancer cells are of critical importance for investigation, prevention, and treatment of cancer. An ideal diagnosis and collection/isolation technique depends on two ingredients. One is the advancement in the investigation of the molecule mechanisms of cancer at the genetic and molecular level, such as determining biomarkers associated with a specific cancer. The other is the development of techniques that are more accurate, more sensitive, and less timeconsuming. Current diagnosis techniques for cancers include analysis of immunophenotyping by pathological section 35, 36 *Address correspondence to dwpang@whu.edu.cn.
www.acsnano.org or flow cytometry, [37] [38] [39] microarray, 40, 41 PCR, [42] [43] [44] karyotyping, 45, 46 and aptamer-based recognition. 47, 48 Each of those techniques has its own limits and advantages. The flow cytometry technique based on immunophenotypic analysis is accurate but costly. Microarray analysis could detect multiplex samples at a time, but its results are less reliable compared to other methods. The PCR-based method has proven to be a highly sensitive diagnostic technique for cell identification, but this method is time-consuming and tends to give false-negative results, especially when low-level signals are expected in the cells. Therefore, developing rapid, economical, highly effective diagnosis techniques for cancer is still an urgent need. As to the cell collection or isolation techniques, magnetic nanoparticle-based cell collection has been used frequently in recent years, replacing the costly flow cytometry and traditional centrifugation. As an alternative to micrometer magnetic bead-based selection, 49, 50 the small size and increased relative surface area of nanoparticles provide enhanced extraction capabilities. [51] [52] [53] Several groups have detected and isolated cancer cells using fluorescent-magnetic nanoparticles based on receptor-ligand interactions. 13, 14, 22, 25, 33, 54, 55 However, only one kind of cancer cells/sample was analyzed in these studies. Tan et al. have successfully used aptamer-conjugated magnetic nanoparticles and aptamer-conjugated fluorescent nanoparticles to collect and detect multiple cancer cells from one sample sequentially, 56 offering a potential for a multiple cancer cells assay. However, two different kinds of nanoparticles had to be prepared separately.
We have previously described avidin-conjugated fluorescent-magnetic-biotargeting multifunctional nanoparticles for visual recognition and rapid isolation of apoptotic cell, which used high-affinity biotinylated annexin V for signal recognition. 23 Here, we have developed monoclonal antibody (mAb)-coupled fluorescent-magnetic-biotargeting multifunctional nanobioprobe (FMBMN) protocols to perform detection and extraction of multiple types of cancer cell targets from complex samples via the high affinity between antigens and antibodies. As the model systems, we used leukemia cells (Jurkat T), prostate cancer cells (LNCaP), red blood cells, human lung fibroblasts (MRC-5), and mixtures of the above-mentioned cells. As specific cell markers, we used CD3 (cluster of differentiation 3) for Jurkat T cells 57, 58 and prostate-specific membrane antigen (PSMA) for prostate cancer cells. 59, 60 We demonstrated that the mAb-coupled FMBMNs have the capability to identify and isolate multiple target cells from complex mixtures effectively, raising the possibility of using such an approach in clinical applications.
RESULTS AND DISCUSSION
Characterization of the mAb-Coupled FMBMNs. We first validate the quality of the fluorescent-magnetic bifunctional nanoparticles by analyzing their physical properties such as the size and specific magnetization (see Figures S1, S2, and S3 in the Supporting Information). We then fabricated different mAb-coupled FMBMNs by coupling the corresponding mAbs to the bifunctional nanoparticles by using an indirect conjugation method based on the high affinity between biotin and avidin, and the interaction between the primary antibody and second antibody, as shown in Figure 1A . In such a design, the mAbs were immobilized on the surface of the fluorescent-magnetic bifunctional nanoparticles ( Figure 1A) . Figure 1B and C shows the fluorescence microscope images of mAbcoupled nanobiobrobes. Both the anti-CD3 mAbcoupled nanobioprobes ( Figure 1B ) and anti-PSMA mAb-coupled nanobioprobes ( Figure 1C ) were clearly monodispersed and retained the expected fluorescence.
In the preparation of mAb-coupled nanobioprobes, the biotinylated goat anti-mouse IgG (Fc specific, note that antibodies consist of two parts: Fab and Fc; 61 of these two parts, the Fab segment is the functional domain, which recognizes the antigen specifically, and Fc is a structural domain) was used to ensure that the Fab segment of anti-CD3 mAbs or anti-PSMA mAbs was on the surface of the nanoparticles, which serves to recognize the target cells and enhances the isolation efficiency. We subsequently confirmed that the mAbs on the nanoparticles could specifically interact with FITC-labeled goat anti-mouse Fab fragments (Fab specific), as demonstrated for the anti-CD3 mAb-coupled nanobioprobes shown in Figure 2 . Analysis of the FITC fluorescence clearly showed the binding of FITClabeled goat anti-mouse Fab fragments (Fab specific) to the anti-CD3 mAb-coupled red nanobioprobes ( Figure 2B and C), indicating that the bioactivity of the anti-CD3 mAbs was preserved during the coupling process. As a negative control, no FITC fluorescence was detected when anti-CD3 mAb-free nanoparticles were incubated with FITC-labeled goat anti-mouse Fab fragments (Fab specific) ( Figure 2D ) or when anti-CD3 mAb-coupled red nanobioprobes were incubated with FITC-labeled goat anti-mouse Fab fragments (Fc specific) ( Figure 2E ). The bioactivity and specificity of anti-PSMA mAb-coupled nanobioprobes were similarly confirmed (data not shown).
Detection of Multiple Types of Target Cancer Cell with mAbCoupled FMBMNs. To confirm the mAb-coupled nanobioprobes have the capability of recognizing the target cells, the anti-CD3 mAb-coupled nanobioprobes and anti-PSMA mAb-coupled nanobioprobes were incubated with cell samples as mentioned in the Experimental Section. For specificity test, the LNCaP cells and red blood cells were used as the controls for the Jurkat T cell experiment with the anti-CD3 mAb-coupled nanobioprobes, while the Jurkat T cells and red blood cells were used as the controls for the LNCaP cell experiment with the anti-PSMA mAb-coupled nanobioprobes as diagramed in Figure 3 . Because the target cancer cells had been stained with fluorescent dyes and the mAb-coupled nanobioprobes contained fluorescent quantum dots, they could be visualized by their different fluorescence when excited under a lamphouse after the experiment. If green fluorescence of nucleus and red fluorescence on the surface of the cell appeared simultaneously, we would conclude that the Jurkat T cell was recognized by the anti-CD3 mAbcoupled nanobioprobes. Similarly, if blue and yellow fluorescence appeared simultaneously, we would conclude that the LNCaP cell was detected by the anti-PSMA mAb-coupled nanobioprobes.
After incubating the labeled cells with the nanobioprobes, the mixtures were subjected to magnetic separation (see Figure S4A in the Supporting Information for the magnetic field strength used). Fluorescent microscopic images of the precipitate were then taken. Figure 4 shows the results of a representative experiment in which the anti-CD3 mAb-coupled nanobioprobes (with red fluorescence emission) and Jurkat T cells were analyzed. The bright-field image revealed nanobioprobes bound to the cell surface ( Figure 4A ), while the strong red fluorescence (form the anti-CD3 Figure 1 were incubated with FITC-labeled goat anti-mouse Fab fragment (Fab specific). The FITC-labeled goat antibody will bind specifically to the nanobioprobe, enabling it to produce green fluorescence under UV due to the FITC. Fluorescent images of anti-CD3 mAb-coupled red FMBMNs (B, C, E) or bifunctional nanoparticles (D) incubated with FITC-labeled goat anti-mouse antibodies. The FITC-labeled goat anti-mouse antibodies bound to mouse anti-CD3 antibodies on the nanobioprobes. Under UV, the FITC produced the green fluorescence (B). Note that there was also red fluorescence from the nanobioprobes. In some nanobioprobes, the red fluorescence was sufficiently strong to produce an overall yellow color for these nanobioprobes. Similarly, when the anti-PSMA mAb-coupled nanobioprobes (with yellow fluorescence emission) and LNCaP cells were used for the test, the nanobioprobes bound to the cell surface were observed in the bright field ( Figure 5A ), and yellow fluorescence (from the anti-PSAM mAb-coupled nanobioprobes) on the cell surface and blue fluorescence (from Hochest 33342) inside the cell were observed (Figure 5B ), indicating the binding of the nanobioprobes to the LNCaP cells. On the other hand, when the anti-PSMA mAb-coupled nanobioprobes were incubated with Jurkat T cells ( Figure 5D and E) and red blood cells ( Figure 5F and G), only nanobioprobes ( Figure 5D and F) and yellow fluorescence (from the nanobioprobes in Figure 5E and G) were observed under fluorescence microscope, indicating the lack of binding of the nanobioprobes to these two cell types. Thus, the anti-PSMA mAb-coupled FMBMNs can specifically recognize the LNCaP cells.
Isolation Figure 3B . After incubation and magnetic separation as described in the Experimental Section, the magnetic precipitate and supernatants were imaged under the fluorescence microscope. As shown in Figure 6 , when samples containing 2 Â 10 5 Jurkat T cells labeled with SYTO 13 and 10 6 red blood cells were treated with anti-CD3 mAbcoupled nanobioprobes, the isolated cells had the nanobioprobes bound to the Jurkat T cell surface as observed in the bright field ( Figure 6A ) and had red fluorescence (from anti-CD3 mAb-coupled nanobioprobes) on the cell surface and green fluorescence (from SYTO 13) inside the cell ( Figure 6B ), indicating that the isolated Jurkat T cells had anti-CD3 mAbcoupled nanobioprobes bound to the surface. On the other hand, the supernatants had smaller cells (compared with Jurkat T cells) in the bright field ( Figure 6C ) and very few green fluorescent spots in the fluorescence field ( Figure 6D ). Thus, the smaller, red blood cells were not bound by the nanobioprobes and thus left in the supernatant, while very few Jurkat T cells (with green fluorescence) were present in the supernatant. Similarly, when 2 Â 10 5 LNCaP cells labeled with
Hochest 33342 and 10 6 red blood cells were mixed and treated with anti-PSMA mAb-couple nanobioprobes, the magnetic precipitate showed cells with nanobioprobes bound to the cell surface in the bright field ( Figure 6E ) and yellow fluorescence (from PSMA mAbcoupled nanobioprobes) on the cell surface and blue fluorescence (from Hochest 33342) inside the cell in the fluorescence field ( Figure 6F ). The supernatants again contained the smaller cells (compared with LNCaP cells), as shown in the bright field ( Figure 6G ) and few blue fluorescence spots in the fluorescence field ( Figure 6H ). Here again, the smaller, red blood cells were not bound by the nanobioprobes and thus left in the supernatant, while very few with LNCaP cells (with blue fluorescence) were present in the supernatant. Efficiency of the mAb-Coupled FMBMNs to Capture the Target Cancer Cells. The above studies clearly demonstrated that both kinds of mAb-coupled nanobioprobes could specifically detect and isolate their target cells. To investigate whether they could be used for effective capture of the target cells, we next analyzed the effect of the incubation time and the amount of nanobioprobes on the efficiency of the mAb-coupled nanobioprobes to capture the target cells. The numbers of each type cells before and after capturing with mAb-coupled nanobioprobes were determined with a hemocytometer to calculate the efficiency of the mAb-coupled nanobioprobes to capture the target cancer cells as described in the Experimental Section, and the results are shown in Figure 7 . The capture efficiency of about 80% was found to be independent of the incubation time of 15 min or longer when using anti-CD3 mAb-coupled nanobioprobes with a concentration of 1. were only nanobioprobes but no cells present after incubating the cells with the nanobioprobes and magnetic isolation (data not shown). Thus, under our experimental conditions, the nanobioprobes could specifically detect and isolate target cells at concentrations as low as 0.01%, suggesting the possibility of such nanobioprobles for clinical applications in the early detection of cancer cells.
CONCLUSION
We have previously successfully employed folate or avidin-conjugated FMBMNs to detect and isolate a single kind of target cell (cancer cells and apoptotic cells) from analytical samples.
14,23,25 Herein, we demonstrated that, by using the mAb-coupled FMBMNs, two different types of tumor cells (leukemia cells and prostate cancer cells) have been successfully detected and extracted from complex samples containing both normal cells and the target cancer cells. The capture efficiencies of the mAb-coupled nanobioprobes for the above-mentioned cancer cells were about 96% and 97%, respectively, under our experimental conditions. We further showed that the mAb-coupled FMBMNs, with the help of a magnet and a fluorescence microscope, could very sensitively detect and isolate target tumor cells at concentrations as low as 0.01% in mixed cell samples within 25 min. To the best of our knowledge, this is the first successful model where the FMBMNs were used for detection and isolation of multiple types of cells. Such a simple, sensitive, efficient, and fast yet low-cost approach offers a potentially very powerful means for detection of multiple cancer cells at early stages.
EXPERIMENTAL SECTION
Materials. Avidin, biotinylated goat anti-mouse IgG polyclonal antibody (Fc specific), fluorescein isothiocyanate (FITC)-labeled goat anti-mouse Fab fragments (Fab specific), FITC-labeled goat anti-mouse Fab fragments (Fc specific), and poly-lysine were purchased from Sigma-Aldrich. Mouse antihuman anti-CD3 monoclonal antibody (mAb), mouse antihuman anti-PSMA monoclonal antibody (mAb), nucleic acid stain SYTO13, and Hochest 33342 were obtained from Invitrogen Corp. Jurkat T cells (human peripheral blood leukemia T cells), LNCaP cells (human prostate cancer cells), and MRC-5 cells (human lung fibroblasts) were purchased from China Type Culture Collection, and human blood samples pretreated with anticoagulant from Renmin Hospital of Wuhan University. All the media used for cell culture were obtained from Gibco Corp. All other chemical reagents were purchased from Shanghai Chemical Reagent Company. The magnetic scaffold (magnetic particle concentrator) was purchased from Promega (USA).
Preparation of Avidin-Conjugated Fluorescent-Magnetic Multifunctional Nanoparticles. The avidin-conjugated fluorescent-magnetic nanoparticles were prepared as described. 23 Briefly, core/shell CdSe/ZnS quantum dots (QDs) were first synthesized in organic phase.
14 Nano-γ-Fe 2 O 3 particles and hydrazine-treated poly-(styrene/acrylamide) nanospheres were prepared as previously described. 23 A 2 mL suspension of the hydrazine-treated poly-(styrene/acrylamide) copolymer nanospheres, CdSe/ZnS QDs (3.0 mg), and nano-γ-Fe 2 O 3 particles (2.0 mg) were mixed and swelled in a chloroform/butanol solvent (5:95 by volume) and then ultrasonicated for 60 min. The mixture was centrifuged for 5 min at 2790g followed by washing three times with butanol to produce the fluorescent-magnetic bifunctional nanoparticles. Then avidin-coupled fluorescent-magnetic multifunctional nanoparticles were obtained by incubating aldehyde-containing avidin (2.8 mg/mL, 240 μL) with fluorescent-magnetic bifunctional nanoparticles (2.4 mL of a 20.0 mg/mL suspension) for 6 h at room temperature in the dark after the mixture was diluted to 3.0 mL. The final products were washed five times with phosphate-buffered saline (PBS, 0.1 mol/L, pH 6.8) and then stored at 4°C in PBS (0.1 mol/L, pH 6.8).
Preparation of Monoclonal Antibody (mAb)-Coupled FMBMNs. The avidin-conjugated red or yellow (color of luminescence) fluorescent-magnetic bifunctional nanoparticles (20 mg/mL, 200 μL) were first incubated with biotinylated goat anti-mouse Fc specific polyclonal antibody (2 mg/mL, 200 μL) for 30 min at 4°C, followed by washing with 1 Â PBS (137 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L Na 2 HPO 4 , 1.8 mmol/L KH 2 PO 4 , pH 7.4) three times by centrifuging at 15000g/5 min to remove the superfluous nonspecific adsorbent antibodies. Then the biotinylated goat anti-mouse antibody coupled red-or yellowcolored fluorescent-magnetic multifunctional nanoparticles were incubated with mouse anti-human anti-CD3 mAb or mouse anti-human anti-PSMA mAb, respectively, for 60 min at 4°C. After washing with 1 Â PBS three times by centrifuging at 15000g/5 min to remove the superfluous nonspecific adsorbent mAbs, the concentration of products was determined as described before. 62 The products were stored at 4°C before use. Validating the Bioactivity of the mAb-Coupled FMBMNs. The bioactivity of the mAb-coupled FMBMNs was detected according to a published procedure. 11 Briefly, the mAb-coupled FMBMNs (0.2 mL, with a concentration of 10 Â 10 10 nanobioprobes/mL in 0.1 mol/L pH 7.2 PBS) were incubated with FITC-labeled goat anti-mouse antibody (Fc specific) for 60 min at 4°C with gentle shaking, followed by washing 10 times with PBS to remove the unbound FITC-labeled goat anti-mouse antibody. The final products were analyzed using a fluorescence microscope (Nikon Eclipse TE2000-U inverted fluorescence microscope). To eliminate the effect of nonspecific absorption, a control experiment was carried out as above except that the mAbcoupled fluorescent-magnetic multifunctional nanoparticles were replaced with biotinylated goat anti-mouse Fc specific polyclonal antibody conjugated fluorescent-magnetic nanoparticles.
Cell Culture and Dyeing. Jurkat T cells (human peripheral blood leukemia T cells) and MRC-5 cells (human lung fibroblasts) were grown in 1640 medium with 10% fetal bovine serum, 100 U/mL penicillin G sodium, and 0.1 mg/mL streptomycin sulfate. LNCaP cells (human prostate cancer cells) were cultured in F12 medium with 10% fetal bovine serum, 100 U/mL penicillin G sodium, and 0.1 mg/mL streptomycin sulfate. Red blood cells were obtained from a healthy volunteer. The cell density was determined using a hemocytometer, prior to all experiments. After dispersing in cell media buffer and subsequent centrifugation at 1000g/5 min three times, the cells were finally dispersed in 1 mL of cold 1 Â PBS. During all experiments, the cells were kept in an ice bath at 4°C. , and 9 Â 10 10 nanobioprobes/mL) of nanobioprobes were incubated with the cell samples for 15 min, respectively. Then, a magnetic field produced by a magnet was introduced to the sample tubes, and after 2 min the target cells were precipitated at the tube wall while the supernatants were collected using a pipet. All the supernatants were put together, diluted with 1.0 mL of buffer, and subsequently counted with a hemocytometer. After magnetic separation, the number of each type of cells before and after isolation with mAb-coupled nanobioprobes was determined with a hemocytometer to calculate the efficiency of the mAb-coupled nanobioprobes to capture the target cancer cells.
Determining the Sensitivity for Detecting and Isolating Rare Target Cancer Cells. A PDMS (polydimethylsiloxane) chip with a hole 1 cm in diameter was stuck on the surface of a glass slide ( Figure  S5 in the Supporting Information). After blocking with 1% bovine serum albumin (BSA), a cell recognition and isolation experiment was performed in the hole described as follows. First, and 10 2 cells/mL, respectively). The cells were added to 10 reaction vessels after being divided into 10 equal aliquots. Subsequently, the MRC-5 cells (a type of normal cells used here to further confirm the specificity of the mAb-coupled nanobioprobes) were added into the same vessels with a final concentration of 10 6 cell/mL, mixing with the target cancer cells in 1 mL of buffer. Finally, the corresponding nanobioprobes were added into the mixture. After incubation, the cells were isolated with a magnet placed under the glass slide ( Figure  S5 in the Supporting Information) and washed three times with 1 Â PBS. After taking away the PDMS chip, the glass slide was directly observed under a confocal microscope (the spinningdisk confocal microscope (Andor Revolution XD) was equipped with an Olympus IX 81 microscope, a Nipkow disk-type confocal unit (CSU 22, Yokogawa), a CO 2 online culture system (INUBG2-PI), and an EMCCD (Andor iXon DV885K single photon detector)).
